email icon Email   printer icon PDF

Pulmonary Transplantation Session Highlights

Pulmonary Transplant Program Committee Members

The Pulmonary Council is looking forward with great excitement to the ISHLT annual scientific program in Montreal April 2013. Council members and the Program Committee have worked diligently to create a program that includes several valuable sessions and symposiums that are vital to setting the tone for an outstanding educational forum for all ISHLT attendees.

The scientific program itself is filled with vital symposia and sessions presenting a forum for challenging debates and discussions on important issues regarding lung transplantation.

There are eight total symposia throughout the meeting, which cover a broad range of important topics. Some of these are collaborative efforts with other councils (including pathology, basic science, nursing, health science and allied health, and pharmacy).

Along with the scientific program, there are a large number of original scientific investigations focused on both basic and clinical science that were submitted for the meeting. These topics will be highlighted in six oral presentation sessions (thirty-six abstracts), eighteen mini-oral presentations and more than eighty posters for presentation.

Translational science will be highlighted in the "Bench to Bedside" session. Topics will range from BOS to infection.

There will be several sessions highlighting antibody mediated rejection (AMR) in lung transplantation. AMR has become increasingly more recognized over the last several years; however, there still is considerable controversy on its diagnosis, unique features and treatment. Two symposia in collaboration with the pathology and basic science councils will focus on discussions that will hopefully lead to better understanding of this issue. The interest in the current topic is also featured in the oral, mini-oral and poster sessions.

Bronchiolitis obliterans remains a major complication after lung transplant and is the major cause for late morbidity and mortality. We now understand that different processes can lead to allograft dysfunction. The term chronic lung allograft dysfunction (CLAD) has been incorporated to include these other processes. One symposium will provide state-of-the-art information on these issues and an abstract session will update us on its pathophysiology.

Another area of significant interest to our council members is how to best support patients with end-stage lung disease while bridging them to a successful lung transplant. A symposium will bring experts together to discuss techniques of bridging patients that are critically ill prior to transplant. A Sunrise symposium will discuss patient selection as part of this ongoing debate.

Immunosuppression is also featured prominently with an abstract session presenting interesting conundrums on the use of different therapeutic agents. This session will be nicely paired with a symposium on T cells and their roles post-transplant.

Other interesting sessions include outcomes after lung transplantation. Primary graft dysfunction is featured in an abstract session and a Sunrise symposium will discuss patient-reported outcomes. Two additional Sunrise symposia have been planned: one will assess anastomotic issues and the utility of bronchoscopy; the other will present different lung allocation systems around the world and discuss their merits and limitations.

Finally, common topics of interest that will also be discussed include a joint Saturday symposium with the Pharmacy council which assesses the journey of a cystic fibrosis patient through transplant. It discusses many unique pharmacologic, infectious challenges that this group of patients face, while undergoing lung transplantation.

We look forward to an exciting annual meeting that will stir discussion and add further momentum to the already energetic academic lung transplant community.

To read additional session highlights from other disciplines, go to In The Spotlight - Abstract Session Highlights.